NASDAQ:ATXI Avenue Therapeutics (ATXI) Stock Price, News & Analysis $0.45 -0.13 (-21.66%) As of 08/28/2026 10:14 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsInsider TradesSEC Filings About Avenue Therapeutics Stock (NASDAQ:ATXI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Avenue Therapeutics alerts:Sign Up Key Stats Today's Range$0.45▼$0.4950-Day Range$0.25▼$0.5852-Week Range$0.15▼$0.97Volume5,140 shsAverage Volume6,068 shsMarket Capitalization$1.49 millionP/E Ratio0.02Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Avenue Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for disorders of the central nervous system, with an initial emphasis on acute pain management. The company’s research and development efforts are centered on reformulating established active pharmaceutical ingredients to address unmet needs in hospital and outpatient settings, aiming to improve safety profiles, reduce opioid exposure and support enhanced patient recovery. The company’s lead product candidate is intravenous tramadol, a unique non-solicited opioid analgesic that combines dual mechanisms of action to manage moderate to severe acute pain. Avenue has completed pivotal Phase 3 clinical trials and submitted a New Drug Application to the U.S. Food and Drug Administration, seeking approval to introduce the first IV tramadol formulation in the United States. If approved, the therapy is expected to offer clinicians an alternative to existing intravenous opioids while leveraging a lower potential for respiratory depression and abuse. Avenue Therapeutics is headquartered in the United States and conducts its operations through collaborations with contract research organizations and commercial partners. The company is led by a management team with extensive experience in pharmaceutical development, regulatory strategy and product commercialization, and it continues to explore additional central nervous system pipeline opportunities designed to leverage its formulation expertise and address high-unmet medical needs.AI Generated. May Contain Errors. Read More Receive ATXI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avenue Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATXI Stock News HeadlinesAvenue Therapeutics Inc.February 10, 2026 | barrons.comAvenue Therapeutics announces Baergic Bio acquisition by AxsomeNovember 6, 2025 | msn.comMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altucher is hosting a free masterclass revealing what he says is locked inside a sealed briefcase detailing Musk's plans. Attendees who join early can also access a $1,000 bonus offer included with the presentation.August 30 at 1:00 AM | Paradigm Press (Ad)Avenue Therapeutics Reports Positive Earnings Amid ChallengesAugust 22, 2025 | msn.comUniversity Avenue will be closed for repair due to a sinkhole in MorgantownJuly 20, 2025 | msn.com17-year-old dies from gunshot wound near Colley Avenue, police sayJuly 20, 2025 | msn.comCrash involving a fire engine reported on Tennessee Avenue in Bond HillJuly 20, 2025 | msn.comKatipunan Avenue now passable after billboard collapse forces temporary closureJuly 20, 2025 | msn.comSee More Headlines ATXI Stock Analysis - Frequently Asked Questions How have ATXI shares performed this year? Avenue Therapeutics' stock was trading at $0.6802 at the start of the year. Since then, ATXI shares have decreased by 33.5% and is now trading at $0.4520. How were Avenue Therapeutics' earnings last quarter? Avenue Therapeutics, Inc. (NASDAQ:ATXI) issued its quarterly earnings data on Friday, August, 9th. The company reported ($6.43) earnings per share for the quarter, missing analysts' consensus estimates of ($1.05) by $5.38. When did Avenue Therapeutics' stock split? Avenue Therapeutics shares reverse split on the morning of Friday, April 26th 2024.The 1-75 reverse split was announced on Friday, April 26th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 26th 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. When did Avenue Therapeutics IPO? Avenue Therapeutics (ATXI) raised $30 million in an initial public offering on Tuesday, June 27th 2017. The company issued 5,000,000 shares at a price of $5.00-$7.00 per share. Oppenheimer acted as the underwriter for the IPO and National Securities Corp. was co-manager. How do I buy shares of Avenue Therapeutics? Shares of ATXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Avenue Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Avenue Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), Broadcom (AVGO), GE Aerospace (GE), CrowdStrike (CRWD) and Novo Nordisk A/S (NVO). Company Calendar Last Earnings8/09/2024Today8/30/2026Next Earnings (Estimated)11/13/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ATXI CIK1644963 Webwww.avenuetx.com Phone(781) 652-4500FaxN/AEmployees4Year Founded2015Profitability EPS (Trailing Twelve Months)($0.85) Trailing P/E Ratio0.02 Forward P/E RatioN/A P/E GrowthN/ANet Income-$10.38 million Net MarginsN/A Pretax MarginN/A Return on Equity-471.57% Return on Assets-296.50% Debt Debt-to-Equity RatioN/A Current Ratio2.70 Quick Ratio2.70 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.92 per share Price / Book0.24Miscellaneous Outstanding Shares3,295,000Free Float2,017,000Market Cap$1.49 million OptionableNot Optionable Beta-0.20 Social Links 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:ATXI) was last updated on 8/30/2026 by MarketBeat.com Staff. From Our PartnersThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredA $382 trillion migration and the position no one is talking aboutTrump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...Awesomely | SponsoredDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...Porter & Company | SponsoredNow that SpaceX is public, buy this ticker (no, not SpaceX or Tesla)The SpaceX IPO wasn't the big trade - according to Larry Benedict, founder of The Opportunistic Trader, it was...Brownstone Research | SponsoredSPDR Gold just lost $14 billion.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...Behind the Markets | SponsoredBuy These Stocks Before August 31stKeith Kaplan has invested $17 million into his own AI research platform, now used by 180,000 investors worldwi...TradeSmith | SponsoredWhy the Treasury still prices gold at 42 dollars an ounceThe U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades n...Golden Portfolio | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avenue Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avenue Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
